Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 17/20 | 0.49 |
| ▸ | RARB | P10826 | 14/20 | 0.49 |
| ▸ | RARG | P13631 | 14/20 | 0.49 |
| ▸ | RARA | P10276 | 10/20 | 0.49 |
| ▸ | RXRB | P28702 | 9/20 | 0.49 |
| ▸ | RXRG | P48443 | 9/20 | 0.49 |
| ▸ | CYP26A1 | O43174 | 3/20 | 0.41 |
| ▸ | CYP26B1 | Q9NR63 | 2/20 | 0.41 |
| ▸ | RECQL | P46063 | 2/20 | 0.40 |
| ▸ | BLM | P54132 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | GMNN | O75496 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4586461 | 1.00 | RXRA (0.49) | RXRARARBRARGRARARXRB | |
| SCHEMBL6261090 | 0.84 | RARG (0.52) | RXRARARBRARGRARARXRB | |
| SCHEMBL6261082 | 0.84 | RARG (0.52) | RXRARARBRARGRARARXRB | |
| SCHEMBL6260299 | 0.83 | RXRA (0.72) | RXRARARBRARGRARARXRB | |
| SCHEMBL6260306 | 0.83 | RXRA (0.72) | RXRARARBRARGRARARXRB | |
| SCHEMBL6516792 | 0.81 | RXRA (0.69) | RXRARARBRARGRARARXRB | |
| SCHEMBL6516794 | 0.81 | RXRA (0.47) | RXRARARBRARGRARARXRB | |
| SCHEMBL6429289 | 0.81 | RXRA (0.53) | RXRARARBRARGRARARXRB | |
| SCHEMBL27582113 | 0.81 | RXRA (0.53) | RXRARARBRARGRARARXRB | |
| SCHEMBL6260911 | 0.79 | RXRA (0.49) | RXRARARBRARGRARARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1453496-A4 | COMPOSITION AND METHOD FOR MODULATING BAR/FXR RECEPTOR ACTIVITY | ALLERGAN INC (US) | 2008-10-08 | — | — | EP | disclosed |
| EP-1185277-B1 | Use of FXR synthetic ligands for the treatment of diseseas linked to cholesterol imbalance and colon cancer | ALLERGAN INC (US) | 2005-10-26 | — | — | EP | disclosed |
| US-6906057-B1 | Methods for modulating FXR receptor activity | ALLERGAN, INC. (US) | 2005-06-14 | — | — | US | disclosed |
| US-20050004165-A1 | Composition and method for modulating BAR/FXR receptor activity | FORMAN BARRY M (US) | 2005-01-06 | — | — | US | disclosed |
| EP-1185539-B1 | ORGANOSILYL COMPOUNDS HAVING NUCLEAR HORMONE RECEPTOR MODULATING ACTIVITY | ALLERGAN INC (US) | 2004-12-01 | — | — | EP | disclosed |
| EP-1453496-A2 | COMPOSITION AND METHOD FOR MODULATING BAR/FXR RECEPTOR ACTIVITY | Allergan, Inc. (US) | 2004-09-08 | — | — | EP | disclosed |
| US-20030144360-A1 | Composition and method for modulating BAR/FXR receptor activity | ALLERGAN SALES, INC. | 2003-07-31 | — | — | US | disclosed |
| WO-2003043581-A2 | COMPOSITION AND METHOD FOR MODULATING BAR/FXR RECEPTOR ACTIVITY | ALLERGAN, INC. (US) | 2003-05-30 | — | — | WO | disclosed |
| US-6452032-B1 | ANTAGONISTS, AGONISTS, OR INVERSE AGONISTS PARTICULARLY FOR RETINOID AND FARNESOID RECEPTORS; REGULATORS OF CELL PROLIFERATION AND DIFFERENTIATION AND OF LIPID METABOLISM; DERMATOSES SUCH AS ACNE, PSORIASIS, ICTHYOSIS AND ECZEMA | ALLERGAN SALES, LLC | 2002-09-17 | — | — | US | disclosed |
| EP-1185277-A1 | METHODS FOR MODULATING FXR RECEPTOR ACTIVITY | Allergan Sales, Inc. (US) | 2002-03-13 | — | — | EP | disclosed |
| EP-1185539-A1 | ORGANOSILYL COMPOUNDS HAVING NUCLEAR HORMONE RECEPTOR MODULATING ACTIVITY | Allergan Sales, Inc. (US) | 2002-03-13 | — | — | EP | disclosed |
| WO-2000076523-A1 | METHODS FOR MODULATING FXR RECEPTOR ACTIVITY | ALLERGAN SALES, INC. (US) | 2000-12-21 | — | — | WO | disclosed |
| WO-2000077011-A1 | ORGANOSILYL COMPOUNDS HAVING NUCLEAR HORMONE RECEPTOR MODULATING ACTIVITY | ALLERGAN SALES, INC. (US) | 2000-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004165-A1 | Composition and method for modulating BAR/FXR receptor activity | NR1H4, FXR1, GPBAR1 | RXRA 35/4885RARB 181/4885RARG 150/4885 |
| US-20030144360-A1 | Composition and method for modulating BAR/FXR receptor activity | NR1H4, FXR1, GPBAR1 | RXRA 35/4885RARB 181/4885RARG 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.